Beta Cells in Diabetes
Steering Committee
Irl B. Hirsch, MD
University of Washington
School of Medicine
John L. Leahy, MD
University of Vermont
College of Medicine
Kevin A. Peterson, MD, MPH
University of Minnesota
Medical School
Doron Schneider, MD, FACP
Abington Health
Jay Shubrook, DO, FACOFP, FAAFP
Touro University California
College of Osteopathic Medicine
Program Overview
Initiative
The Beta Cells in Diabetes initiative was designed to engage primary care physicians in pathophysiology-based clinical decision making through an interactive educational format that stimulates debate and encourages physicians to incorporate new science into their treatment regimens for patients with type 2 diabetes.
Audience
Primary care physicians
Supporters
This initiative is supported by an independent medical education grant from Novo Nordisk Inc., Lilly USA, LLC, and Merck & Co., Inc.
Program Elements
Beta Cells in Diabetes Working Group
The Endocrine Society convened a working group of basic researchers, clinical endocrinologists, and primary care physicians who recommended developing new systems to address common barriers to glycemic control including exploring new educational approaches to promote pathophysiology-based clinical practices.
β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment
Co-published in Diabetes Care and the Journal of Clinical Endocrinology and Metabolism, the paper called for the creation of a comprehensive resource to aid primary care physicians in the interpretation of concepts of disease pathogenesis and to improve medical decision-making in type 2 diabetes.
A comprehensive, online resource of publications, interactive case studies, and other continuing medical education activities designed to engage primary care physicians in pathophysiology-based clinical decision making.
A 10-episode limited series featuring members of the editorial board and guest speakers covering critical developments in type 2 diabetes pathophysiology, medication, and management, The speakers discuss new concepts, emerging research and current therapeutic options.
Program partner:
In collaboration with: